secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2025-04-18T23:59:59+00:00
Accession:  0001641172-25-005466
Event type: regulatory
Sentiment:  neutral
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq Panel grants Lixte extension to July 3, 2025 for equity compliance
-------------------------------------------------------------------------

- Lixte received extension from Nasdaq Hearings Panel after April 3 hearing on equity deficiency.
- Must demonstrate minimum $2.5M stockholders' equity by July 3, 2025 to remain listed.
- Common stock (LIXT) and warrants (LIXTW) continue trading on Nasdaq during extension.
- Company pursuing measures but warns no assurance of regaining compliance; delisting risk persists.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000164117225005466/0001641172-25-005466-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000164117225005466/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-005466

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer